Investors in Haemonetics Corporation (NYSE:HAE) had a good week, as its shares rose 6.8% to close at US$68.19 following the release of its annual results. Haemonetics reported US$1.4b in revenue, roughly in line with analyst forecasts, although statutory earnings per share (EPS) of US$3.31 beat expectations, being 8.7% higher than what the analysts expected. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.

Our free stock report includes 1 warning sign investors should be aware of before investing in Haemonetics. Read for free now.NYSE:HAE Earnings and Revenue Growth May 11th 2025

Taking into account the latest results, the eight analysts covering Haemonetics provided consensus estimates of US$1.32b revenue in 2026, which would reflect a measurable 3.0% decline over the past 12 months. Statutory earnings per share are predicted to accumulate 9.1% to US$3.64. In the lead-up to this report, the analysts had been modelling revenues of US$1.33b and earnings per share (EPS) of US$3.90 in 2026. So it looks like there's been a small decline in overall sentiment after the recent results - there's been no major change to revenue estimates, but the analysts did make a minor downgrade to their earnings per share forecasts.

See our latest analysis for Haemonetics

The consensus price target held steady at US$93.30, with the analysts seemingly voting that their lower forecast earnings are not expected to lead to a lower stock price in the foreseeable future. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. Currently, the most bullish analyst values Haemonetics at US$120 per share, while the most bearish prices it at US$68.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that revenue is expected to reverse, with a forecast 3.0% annualised decline to the end of 2026. That is a notable change from historical growth of 10% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 8.2% per year. It's pretty clear that Haemonetics' revenues are expected to perform substantially worse than the wider industry.

Story Continues

The Bottom Line

The biggest concern is that the analysts reduced their earnings per share estimates, suggesting business headwinds could lay ahead for Haemonetics. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Haemonetics' revenue is expected to perform worse than the wider industry. The consensus price target held steady at US$93.30, with the latest estimates not enough to have an impact on their price targets.

With that in mind, we wouldn't be too quick to come to a conclusion on Haemonetics. Long-term earnings power is much more important than next year's profits. We have forecasts for Haemonetics going out to 2028, and you can see them free on our platform here.

Don't forget that there may still be risks. For instance, we've identified  1 warning sign for Haemonetics that you should be aware of.

Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.